Plasma myostatin-immunoreactive protein is increased after prolonged bed rest with low-dose T3 administration

J Gravit Physiol. 1999 Oct;6(2):11-5.

Abstract

It has been hypothesized that myostatin, a newly identified member of the transforming growth factor-beta (TGF-beta) family of proteins, acts as a negative regulator of skeletal muscle growth. Because bed rest induced muscle atrophy results from a decreased rate of muscle protein synthesis, we hypothesized that circulating levels of myostatin would be increased following prolonged bed rest. Twelve men (age, 35.8 +/- 4.6 yr; height, 175.7 +/- 2.3 cm; weight, 74.8 +/- 3.5 kg; mean +/- SE) were confined to bed for 25 days at 6 degrees head-down tilt while receiving triiodothyronine (T3; 50 micrograms/day) to accelerate protein loss. Total lean body and appendicular skeletal muscle mass were determined by dual energy x-ray absorptiometry (DEXA) before and after the bed rest period. Plasma myostatin-immunoreactive protein was measured in blood samples obtained after an overnight fast 5 days prior to, and on the 25th day of bed rest. Lean body mass decreased an average 2.2 kg (p < 0.0001). Appendicular skeletal muscle accounted for a majority of the lean body mass loss. On day 25 of bed rest, plasma myostatin-immunoreactive protein was 12% higher (p = 0.01) than measured at baseline. These data support the idea that myostatin regulates muscle growth in humans and that it may be a novel target for interventions aiming to reduce space flight induced muscle atrophy.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Bed Rest / adverse effects*
  • Body Composition
  • Head-Down Tilt / adverse effects
  • Humans
  • Male
  • Muscle, Skeletal / drug effects
  • Muscular Atrophy / etiology
  • Muscular Atrophy / metabolism*
  • Myostatin
  • Thyrotropin / blood
  • Thyroxine / blood
  • Transforming Growth Factor beta / blood
  • Transforming Growth Factor beta / metabolism*
  • Triiodothyronine / blood
  • Triiodothyronine / pharmacology*
  • Weightlessness Simulation / adverse effects
  • Weightlessness Simulation / methods

Substances

  • MSTN protein, human
  • Myostatin
  • Transforming Growth Factor beta
  • Triiodothyronine
  • Thyrotropin
  • Thyroxine